[Click eStock] "Mediana Transforms into a Platform Company in the Medical AI Industry"

On the 11th, KB Securities analyzed that Mediana is actively transforming into a medical AI platform company by integrating artificial intelligence (AI) technology with its existing hardware capabilities.

Mediana is a manufacturing specialist company that produces and supplies medical devices such as defibrillators and patient monitors under its own brand and ODM methods. It has expanded its portfolio by adding new product lines such as body composition analyzers and consumable catheters, and recently entered the medical AI business through technological collaboration with Selvas AI.

As of last year, Mediana's sales composition consisted of 42.6% from patient monitors, 28.9% from defibrillators, 7.4% from other products, and 21.1% from merchandise and others. Based on its existing product lines, the company is aiming to transition into a platform business that fuses new technologies.

Han Jeyoon, a researcher at KB Securities, explained, "Mediana officially announced its entry into the medical AI business at the recent shareholders' meeting," adding, "Going forward, it plans to provide its own medical AI solutions by integrating Selvas AI's software capabilities with its existing hardware."

In particular, Mediana plans to develop a single platform by starting with real-time biometric signal monitoring services through CMS (Central Monitoring System) using a centralized integrated control method, and equipping it with various AI services. The potential for expansion into new services such as telemedicine, AI diagnostics, and disease prediction using the collected data is drawing attention.

The researcher stated, "Through the data collected in this process, expansion into various businesses such as telemedicine, AI diagnostics, and disease prediction solutions is expected, which in turn is anticipated to lead to mid- to long-term valuation rerating."

Additionally, on the 8th, Mediana strengthened its competitiveness in the market by completing the establishment of an alliance (MASA) with leading domestic medical AI companies including Vuno, JLK, and Selvas AI.

Researcher Han Jeyoon said, "Various medical AI services will be commercialized through Mediana's CMS," and added, "Starting with the integration of each company's core AI solutions such as stroke and cardiac arrest prediction, joint development solutions from the alliance are expected to be integrated in the future."

He continued, "The diverse service lineup secured in this way is expected to significantly contribute to early market penetration and market share acquisition," emphasizing, "It is important to pay attention to the future business development process as Mediana's platform is expected to benefit the most from this alliance establishment."